Stryker Corporation (SYK)
NYSE:SYK
Top Page
Stryker
(NYSE:SYK)
Select Model
Select Model
Rating:66Neutral
Price Target:
$359.00
▲(9.57% Upside)
Action:ReiteratedDate:03/24/26
The score is anchored by strong fundamentals and supportive 2026 guidance (durable growth, solid cash generation, improving leverage). It is held back by weak technical conditions (price below major moving averages with negative MACD), a relatively expensive valuation (P/E ~41), and a near-term risk overhang from the recent cybersecurity incident and tariff-related cost headwinds.
Positive Factors
Sustained Revenue Growth
Consistent multi-year revenue expansion to ~$25.1B reflects durable demand across orthopaedics, MedSurg and Neurotechnology. Broad portfolio and cross-selling reduce single-product risk, supporting steady procedure-driven recurring revenues and long-term market share gains.
Negative Factors
Tariff Headwinds
A ~$400M tariff headwind is a sizable structural cost pressure that can erode margins and free cash flow if not offset by pricing or mix. Realized mostly in H1 2026, persistent trade-policy costs reduce operating leverage and complicate long-term margin planning.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Revenue Growth
Consistent multi-year revenue expansion to ~$25.1B reflects durable demand across orthopaedics, MedSurg and Neurotechnology. Broad portfolio and cross-selling reduce single-product risk, supporting steady procedure-driven recurring revenues and long-term market share gains.
Read all positive factors
Stryker (SYK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$125.39B
Dividend Yield0.95%
Average Volume (3M)2.04M
Price to Earnings (P/E)41.4
Beta (1Y)0.69
Revenue Growth10.95%
EPS Growth-18.32%
CountryUS
Employees53,000
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)4.47
Shares Outstanding382,688,700
10 Day Avg. Volume2,672,265
30 Day Avg. Volume2,038,154
Financial Highlights & Ratios
PEG Ratio5.16
Price to Book (P/B)5.99
Price to Sales (P/S)5.35
P/FCF Ratio31.36
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue5.50
Enterprise Value/Gross Profit8.66
Enterprise Value/Ebitda24.74
Forecast
1Y Price Target
$431.35Price Target Upside31.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
EPS Forecast (FY)15.01
Revenue Forecast (FY)$27.34B
Stryker Business Overview & Revenue Model
Company Description
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint re...
How the Company Makes Money
Stryker makes money primarily by selling medical devices, implants, capital equipment, and related consumables and services to healthcare providers.
Key revenue streams
1) Implantable and procedure-based products (recurring, volume-driven): A lar...
Stryker Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down revenue across different regions, revealing where Stryker is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Breaks down revenue across different regions, revealing where Stryker is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Data provided by:
The Fly
The FlyStryker Earnings Call Summary
Earnings Call Date:Jan 29, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 06, 2026
Earnings Call Sentiment Positive
The call emphasized broad-based revenue and earnings strength, record robotics momentum (Mako 4 and installed base >3,000), strong cash generation, and continued margin expansion, while also acknowledging manageable near-term headwinds including tariffs (~$400M in 2026), higher interest expense, competitive pressure in parts of vascular, and some regional capital softness. Guidance for 2026 is constructive (8.0%–9.5% organic growth and $14.90–$15.10 adjusted EPS) and management highlighted operational levers and M&A firepower to support growth.Positive Updates
Strong Top-Line Growth
Organic sales growth of 11.0% in Q4 and 10.3% for full-year 2025, with total sales surpassing $25 billion; U.S. full-year organic growth of 11.2% and international organic growth of 7.5%.
Negative Updates
Tariff Headwinds and Incremental Cost
Management expects full-year 2026 tariff impacts of approximately $400 million, including an incremental $200 million versus 2025 (realized mainly in H1 2026); tariffs contributed to a 10-basis-point Q4 adjusted gross margin decline.
Read all updates
Q4-2025 Updates
Positive
Negative
Strong Top-Line Growth
Organic sales growth of 11.0% in Q4 and 10.3% for full-year 2025, with total sales surpassing $25 billion; U.S. full-year organic growth of 11.2% and international organic growth of 7.5%.
Read all positive updates
Company Guidance
Stryker guided 2026 organic net sales growth of 8.0%–9.5% and adjusted net EPS of $14.90–$15.10, expecting a modestly positive impact from price and a slightly favorable FX effect if rates hold; management sees the same number of selling days and similar seasonality to 2025, anticipates a full‑year tariff headwind of about $400 million (including an incremental ~$200 million realized in H1), forecasts adjusted other income/expense of roughly $420 million, targets an effective tax rate of 15%–16%, and continues to aim for free cash flow conversion of about 70%–80% of adjusted net earnings under its long‑range plan.Stryker Financial Statement Overview
Summary
Income Statement
84
Very Positive
Balance Sheet
76
Positive
Cash Flow
81
Very Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 25.12B | 22.59B | 20.50B | 18.45B | 17.11B |
| Gross Profit | 16.07B | 13.98B | 12.49B | 11.04B | 10.71B |
| EBITDA | 6.31B | 4.94B | 5.06B | 4.02B | 3.61B |
| Net Income | 3.25B | 2.99B | 3.17B | 2.36B | 1.99B |
Balance Sheet | |||||
| Total Assets | 47.84B | 42.97B | 39.91B | 36.88B | 34.63B |
| Cash, Cash Equivalents and Short-Term Investments | 4.10B | 4.49B | 3.05B | 1.93B | 3.02B |
| Total Debt | 14.86B | 14.12B | 13.49B | 13.53B | 12.90B |
| Total Liabilities | 25.42B | 22.34B | 21.32B | 20.27B | 19.75B |
| Stockholders Equity | 22.42B | 20.63B | 18.59B | 16.62B | 14.88B |
Cash Flow | |||||
| Free Cash Flow | 4.28B | 3.49B | 3.14B | 2.04B | 2.74B |
| Operating Cash Flow | 5.04B | 4.24B | 3.71B | 2.62B | 3.26B |
| Investing Cash Flow | -4.87B | -3.00B | -962.00M | -2.92B | -859.00M |
| Financing Cash Flow | 113.00M | -525.00M | -1.59B | -749.00M | -2.37B |
Stryker Technical Analysis
Negative
327.65
Price Trends
361.17
Negative
360.66
Negative
371.47
Negative
Market Momentum
-10.29
Positive
28.04
Positive
9.08
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SYK, the sentiment is Negative. The current price of 327.65 is below the 20-day moving average (MA) of 355.75, below the 50-day MA of 361.17, and below the 200-day MA of 371.47, indicating a bearish trend. The MACD of -10.29 indicates Positive momentum. The RSI at 28.04 is Positive, neither overbought nor oversold. The STOCH value of 9.08 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SYK.
Stryker Risk Analysis
Stryker disclosed 29 risk factors in its most recent earnings report. Stryker reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Stryker Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $48.01B | 46.44 | 10.39% | ― | 0.19% | 65.58% | |
68 Neutral | $103.55B | 48.91 | 12.53% | ― | 21.62% | 54.80% | |
67 Neutral | $112.84B | 28.29 | 9.54% | 2.76% | 5.34% | 13.15% | |
66 Neutral | $125.39B | 41.38 | 15.04% | 0.95% | 10.95% | -18.32% | |
65 Neutral | $17.15B | 25.25 | 5.60% | 1.05% | 5.47% | -23.03% | |
62 Neutral | $182.16B | 33.55 | 12.89% | 1.88% | 6.37% | 142.39% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
SYK
Stryker
327.65
-37.43
-10.25%
ABT
Abbott Laboratories
104.83
-24.10
-18.69%
BSX
Boston Scientific
69.78
-31.02
-30.77%
EW
Edwards Lifesciences
82.67
11.48
16.13%
MDT
Medtronic
87.89
1.63
1.89%
ZBH
Zimmer Biomet Holdings
87.64
-23.41
-21.08%
Stryker Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
Stryker Addresses and Contains Recent Cybersecurity Incident
Negative
Mar 23, 2026
Stryker disclosed that a cybersecurity incident identified and reported to the U.S. SEC on March 11 and 12, 2026 disrupted its corporate network, including its Microsoft environment, but current findings indicate no malicious activity directed at ...
Business Operations and Strategy
Stryker Reports Cybersecurity Incident Disrupting Global IT Systems
Negative
Mar 12, 2026
On March 11, 2026, Stryker Corporation identified a cybersecurity incident that disrupted its global Microsoft-based information technology environment, and on March 12, 2026, Chief Information Security Officer Dave Nathans briefed customers and c...
Business Operations and StrategyFinancial Disclosures
Stryker Investigates Cybersecurity Incident Disrupting IT Systems
Negative
Mar 12, 2026
On March 11, 2026, Stryker Corporation identified a cybersecurity incident that disrupted its global Microsoft information technology environment and affected access to certain systems and business applications. The company activated its cybersecu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.